Latest Articlesddd
Amgen (AMGN): Phase 3b results from LIBERTY study assessing the safety and efficacy of Aimovig™(erenumab) 140 mg in …
Celgene (CELG) and Juno (JUNO) announced the signing of a definitive merger agreement upon which Celgene has agreed to …
Acorda (ACOR) stock was up around 10% reaching over $28 in premarket trading. The stock is trading …
Juno Therapeutics’ (JUNO) stock price orbited the moon after-hours trading yesterday, rising 45%, following a wall street …
The Week in Review #16 More Exciting Rallies in Prohost Picks - The past week and …
Checkpoint inhibitors approved for a few firms as immunotherapy for cancer are increasingly demonstrating their superiority …
VERTEX From Europe, Vertex (VRTX) was informed that the European Commission has granted an extension of the Marketing …
Prohost Letter #416 Part 2 2017 - A YEAR OF BREAKTHROUGH TECHNOLOGIES, BREAKTHROUGH PRODUCTS, IMPROVEMENTS ON …
As part of its ongoing strategy to build an innovative pipeline beyond its two internally-discovered, commercially …
On Dec. 12, 2017, Denali Therapeutics (DNLI) announced the closing of its initial public offering of 15,972,221 shares …
Sangamo’s (SGMO) has abundant positive news since it offered proof of concept and feasibility of its zinc …
The Food and Drug Administration (FDA) accepted the supplemental Biologics License Application (BLA) for Seattle Genetics’ (SGEN) product Adcetris …
Prohost Letter #416 Part 1 The Year In Review - 2017 Unheard of Programs - AN …
Progenics Pharmaceuticals (PGNX) has good news today. The U.S. Food and Drug Administration (FDA) has accepted for review …
The FDA Grants Fast Track Status to DelMar Pharmaceuticals’ Product VAL-083 Dec.26, 2017 – DelMar Pharmaceuticals (DMPI) announced …
Two months ahead of the PDUFA date scheduled for February 28, 2018, the Food and Drug …
Based on statistically significant results from the randomized phase 2 CABOSUN trial in patients with previously …
After years of spending efforts in creating and developing its pipeline products, Portola (PTLA) has just been granted …
UCART19 UCART19 is one of the Cellectis’ (CLLS) lead allogeneic anti-CD19 CAR T-cell products. The word allogeneic is important as it makes …
Juno Therapeutics (JUNO) is one of the casualties that occurred during the 59th American Society of Hematology (ASH) Annual …
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. Accept Privacy policy
